Anti-HPV Functional Testing for Sanitary Pads: Standards, Methods, and Technical Requirements

Anti-HPV functional testing for sanitary pads provides scientific verification of whether feminine hygiene products genuinely inactivate human papillomavirus (HPV), supporting legitimate antiviral performance claims. Performed by accredited third-party laboratories using HPV pseudovirus-based infectivity assays adapted from the ISO 18184 textile antiviral framework, this testing quantifies the antiviral activity rate and log reduction value of treated materials. This article explains the testing principles, sample requirements, methodology, acceptance criteria, and commercial applications of anti-HPV performance evaluation for sanitary napkins.

Technical Overview

Human papillomavirus (HPV) is a small, non-enveloped, double-stranded DNA virus of the Papillomaviridae family. The viral particle consists of an approximately 55–60 nm icosahedral capsid assembled from the L1 major capsid protein and L2 minor capsid protein, enclosing a circular DNA genome of roughly 8 kb. More than 200 HPV genotypes have been identified. High-risk types, particularly HPV 16 and HPV 18, are etiologically linked to cervical cancer and together account for approximately 70% of cervical cancer cases worldwide, while low-risk types such as HPV 6 and HPV 11 are associated with anogenital warts.

Sanitary pads marketed with anti-HPV functionality typically incorporate antiviral agents such as metal-ion materials (silver or zinc based), acidic buffered formulations, cationic biocides, or plant-derived extracts. Because antiviral claims carry regulatory and consumer-protection implications, manufacturers must substantiate these claims through laboratory testing that demonstrates a measurable reduction in HPV infectivity after contact with the product.

A fundamental technical challenge is that HPV exhibits strict tissue tropism and completes its replication cycle only in terminally differentiating epithelial cells; it cannot be efficiently propagated in conventional monolayer cell culture. Routine anti-HPV efficacy testing therefore uses HPV pseudovirions (PsV), which are virus-like particles assembled from authentic L1/L2 capsid proteins packaging a reporter gene plasmid such as luciferase or green fluorescent protein. Pseudovirions mediate a single round of reporter gene expression in permissive indicator cells, enabling quantitative measurement of infectivity, while remaining replication-incompetent and suitable for handling under BSL-2 containment in accredited third-party laboratories.

Testing Samples

Finished Products

Complete sanitary pads, panty liners, and overnight pads in original retail packaging can be tested as received. Testing on the finished product evaluates the combined performance of all layers as they reach the consumer and is the preferred basis for marketing claim substantiation.

Component Materials

• Top sheet nonwoven fabric carrying a functional antiviral coating or finish
• Absorbent core composites of fluff pulp and superabsorbent polymer blended with antiviral additives
• Backsheet films or secondary layers when functional agents are incorporated
• Functional masterbatches, coating solutions, or additive concentrates supplied for formulation characterization

Sample Requirements

• Samples must be unused, within shelf life, and supplied in original packaging
• Typical quantity is 20–40 finished pieces or 200–500 g of material per virus type and contact time, plus retention samples
• The manufacturer should declare the active agent identity, add-on level, and claimed contact time to enable protocol design
• Samples are tested as received; if microbial contamination interferes with the assay, validated surface decontamination such as ultraviolet irradiation is applied, with verification that the antiviral agent is not affected

Testing Items

The core testing items for anti-HPV functional evaluation include:

• Anti-HPV activity rate against HPV 16 pseudovirus and/or HPV 18 pseudovirus, expressed as the percentage reduction in residual infectivity relative to an untreated control
• Antiviral activity value (log reduction, R), calculated in accordance with the ISO 18184 framework
• Time-dependent inactivation profiles at defined contact times, for example 5 minutes, 30 minutes, 2 hours, and 24 hours
• Cytotoxicity evaluation of sample eluates against indicator cells to confirm that any signal reduction reflects viral inactivation rather than cellular toxicity
• Optional testing against low-risk HPV 6 and HPV 11 pseudoviruses for broader claim coverage
• Complementary hygiene and safety items commonly bundled for market compliance, including microbiological limits per GB 15979, pH, and other chemical safety parameters

Testing Methods

Assay Principle

The test is an infectivity reduction assay built on the ISO 18184 textile antiviral methodology, adapted for HPV pseudovirus. The sample is inoculated with a standardized pseudovirus suspension, incubated for a defined contact time, and the virus is then eluted and transferred to indicator cell monolayers. Reporter gene expression measured 48–72 hours after infection is directly proportional to the infectious titer of the eluate. The reduction in reporter signal relative to controls quantifies the antiviral function of the sample.

Test System Preparation

• Indicator cells: HEK293T or 293TT cells, or HaCaT human keratinocytes, cultured in DMEM supplemented with 10% fetal bovine serum
• Pseudovirus production: co-transfection of an L1/L2 capsid expression plasmid with a luciferase reporter plasmid, followed by cell harvest, capsid maturation, purification, and titration
• Virus input adjusted to fall within the linear range of the reporter assay, ensuring robust and reproducible quantification

Test Procedure

• Cut samples into standardized pieces, for example 0.20 g portions, and place in sterile containers
• Inoculate each portion with a defined pseudovirus suspension volume and ensure complete wetting of the material
• Incubate at 25 ± 1 °C (or 37 °C where a more stringent condition is specified) for the defined contact times
• Immediately after contact, add culture medium to elute residual virus, agitate, and collect the eluate
• Inoculate eluates, in serial dilution, onto indicator cells in 96-well plates and incubate for 48–72 hours
• Quantify luciferase luminescence or fluorescence signal for each well and compare treated versus control conditions

Quality Controls

• Untreated reference material control, such as a standard cotton swatch, processed in parallel
• Virus-only control without sample to verify titer stability
• Cell-only background control for baseline signal correction
• Cytotoxicity control using sample eluate without virus, with cell viability assessed by a metabolic assay consistent with the ISO 10993-5 approach
• Test validity requires adequate control virus titer and indicator cell viability of at least 80% in the absence of virus

Calculation and Acceptance Criteria

The antiviral activity rate is calculated as the difference between treated and control infectivity, expressed as a percentage reduction, and the antiviral activity value R is calculated as the base-10 logarithm of the ratio of control to treated infectivity. Consistent with the ISO 18184 threshold for non-enveloped viruses, an antiviral activity value of 1.0 or greater, corresponding to at least 90% inactivation, is generally regarded as evidence of antiviral effectiveness. Many brand specifications target a stricter criterion of 99% inactivation, equivalent to R ≥ 2.0. Reportable results must demonstrate that cytotoxicity does not account for the observed signal reduction.

Applications

• Substantiation of anti-HPV and antiviral marketing claims for retail packaging, advertising, and e-commerce listings, where major platforms require third-party test reports before functional claims are published
• Compliance support under advertising regulations, which prohibit unsubstantiated health and functional claims
• Research and development screening of antiviral formulations, optimization of add-on levels, and material selection
• Batch-to-batch consistency verification in quality control programs
• Due diligence documentation for brand owners, distributors, and importers

It is important to note that a laboratory anti-HPV test report demonstrates antiviral activity of the material under defined assay conditions only. It does not constitute a medical claim of preventing HPV infection, sexual transmission, or cervical cancer. HPV is transmitted primarily through direct skin and mucosal contact, and vaccination together with regular screening remain the recognized primary preventive measures. Product labeling and advertising should therefore avoid disease-prevention statements.

FAQ

Why is a pseudovirus used instead of wild-type HPV?

Wild-type HPV replicates only in differentiating epithelial tissue, and no practical in vitro culture system exists for routine high-titer production. Pseudovirions share the authentic L1/L2 capsid structure and the natural cell entry pathway but package a reporter plasmid, making them quantifiable through reporter readout and incapable of replication beyond a single round. Pseudovirus-based systems are the internationally accepted surrogate for HPV infectivity studies, including neutralization testing of HPV vaccines.

Which HPV types should be tested?

HPV 16 and HPV 18 are the standard targets because they are the predominant high-risk oncogenic types. Manufacturers may add HPV 6 and HPV 11, or additional types such as 31, 33, 45, 52, and 58, for broader claims. Each type requires a separate pseudovirus assay.

What result is needed to support an anti-HPV claim?

A generally accepted benchmark is at least 90% inactivation, equivalent to an antiviral activity value of 1.0 or greater, at the claimed contact time against each tested HPV type, with valid controls and acceptable cytotoxicity. Claims of 99% inactivation require a log reduction of 2.0 or greater.

How long does the testing take?

A standard single-type, single-contact-time evaluation typically requires 4 to 6 weeks, including method suitability checks. Comprehensive studies covering multiple HPV types and multiple contact times may require 6 to 8 weeks.

How many samples should be submitted?

Typically 20 to 40 finished pieces, or 200 to 500 g of component material, per virus type and contact time condition, plus retention samples. Exact quantities are confirmed by the laboratory during protocol review.

Is there a dedicated international standard for anti-HPV testing of sanitary pads?

No HPV-specific product standard currently exists for sanitary pads. Testing laboratories adapt the ISO 18184 textile antiviral framework with an HPV pseudovirus infectivity readout, complemented by cytotoxicity assessment consistent with ISO 10993-5 and general hygiene requirements under GB 15979. Where suspension-phase antiviral testing of active ingredients is needed, methodological references such as ASTM E1052 may also be applied.

Does a passing test report mean the product prevents cervical cancer?

No. The report verifies laboratory antiviral activity of the material under controlled assay conditions only. It does not demonstrate prevention of HPV infection or cervical cancer in real-world use, and products should not carry such medical claims.